Aptar Pharma, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its LuerVax ® intranasal ...

Aptar today announced the expansion of its operations in Mumbai, India to add local production of several pharma inhalation technologies, including Aptar’s pressurized metered dose inhaler (pMDI) ...

Squeeze and Dose is an innovative dosing system designed to elevate the product experience. Engineered for precision and effortless, one-handed operation, it delivers clean, accurate dispensing that ...

We believe in our people, and do our best to develop their knowledge, skills and abilities. This allows us to help them achieve their potential and ensures that Aptar’s success and growth. Learning ...

Particulate contamination and product cleanliness are primary concerns in the pharmaceutical market. The latest EMA GMP Annex 1 revision requires that pharmaceutical companies establish more stringent ...

Aptar Pharma offers decades of experience in providing customers with technology and scientific service solutions to todays’ nasal drug delivery challenges. With specialized nasal drug delivery ...

(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 6% to over $1 billion for the first time, and core ...

Aptar announced today that Julie Xing has joined its Board of Directors. With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie’s leadership approach ...

Aptar Beauty, a leading and innovative dispensing solutions provider for beauty brands around the world has acquired iD SCENT, an expert in full paper fragrance sampling solutions that present ...

Aptar today highlighted how its patented, high performance airless dispensing innovation is enabling prestige beauty brands to advance sustainability without compromising performance or luxury.

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced continued progress on its awarded research contract with the U.S. Food and Drug ...

Aptar announced today that it has entered into exclusive negotiations with respect to a potential acquisition of all outstanding shares of Voluntis, a pioneer in digital therapeutics. AptarGroup, Inc.